Literature DB >> 12718819

Demographic and immune correlates of human herpesvirus 8 seropositivity in Malawi, Africa.

Stacia M DeSantis1, Chou-Pong Pau, Lennox K Archibald, Okey C Nwanyanwu, Peter N Kazembe, Hamish Dobbie, William R Jarvis, Janine Jason.   

Abstract

BACKGROUND: In the USA, human herpesvirus 8 (HHV-8) is associated with Kaposi's sarcoma (KS) and HIV infection. We examined HHV-8 seroprevalence in a Malawian cohort, and assessed its relationship with HIV, KS, demographic characteristics, and immune findings.
METHODS: In 1997 and 1998, blood samples were obtained from 272 hospitalized Malawian patients, for whom demographic information was obtained, and 24 healthy volunteers without demographic data. We used enzyme immunoassays to assess seroprevalence and antibody titers to peptide antigens derived from HHV-8 K8.1 and ORF65-encoded proteins. Intracellular cytokines and cell surface antigens were assessed with four-color flow cytometry. Data were analyzed using non-parametric univariate and regression analytic techniques.
RESULTS: The rates of HHV-8 seroprevalence to either or both HHV-8 peptides were 67% for the patients and 54% for the healthy volunteers. Seroprevalence increased with patients' age (P<0.001) but was not associated with HIV status, percentage of lymphocytes expressing CD4, or KS (n=10). Seropositive females had lower antibody titers to both peptides than did males (medians: 455 versus 1361 for K8.1, P<0.001; and 268 versus 405 for ORF65, P=0.044). For the healthy volunteers, the percentage of CD8+ cells producing IFN-gamma after stimulation was significantly lower in ORF65-specific antibody-positive persons (medians: 24% versus 57%, P=0.008).
CONCLUSIONS: In Malawi, HHV-8 is endemic and is not associated with HIV infection or HIV severity. Seroprevalence rates increase in childhood, and, most steeply in adolescence. Titers are higher in seropositive males than in sero-positive females. The immune effects of HHV-8 in healthy adults are consistent with chronic inhibition of type 1 cytotoxic T-cell responsiveness, independent of HIV status.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12718819     DOI: 10.1016/s1201-9712(02)90159-1

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

Review 1.  Kaposi sarcoma.

Authors:  Ethel Cesarman; Blossom Damania; Susan E Krown; Jeffrey Martin; Mark Bower; Denise Whitby
Journal:  Nat Rev Dis Primers       Date:  2019-01-31       Impact factor: 52.329

Review 2.  Epidemiology and transmission of Kaposi's sarcoma-associated herpesvirus.

Authors:  Veenu Minhas; Charles Wood
Journal:  Viruses       Date:  2014-11-04       Impact factor: 5.048

3.  Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study.

Authors:  Nader Kim El-Mallawany; William Kamiyango; Jeremy S Slone; Jimmy Villiera; Carrie L Kovarik; Carrie M Cox; Dirk P Dittmer; Saeed Ahmed; Gordon E Schutze; Michael E Scheurer; Peter N Kazembe; Parth S Mehta
Journal:  PLoS One       Date:  2016-04-15       Impact factor: 3.240

Review 4.  HHV-8 Seroprevalence and Genotype Distribution in Africa, 1998⁻2017: A Systematic Review.

Authors:  Elizabeth M Etta; Doyinmola P Alayande; Lufuno G Mavhandu-Ramarumo; George Gachara; Pascal O Bessong
Journal:  Viruses       Date:  2018-08-27       Impact factor: 5.048

5.  Diverse genotypes of Kaposi's sarcoma associated herpesvirus (KSHV) identified in infant blood infections in African childhood-KS and HIV/AIDS endemic region.

Authors:  F C Kasolo; J Spinks; H Bima; M Bates; U A Gompels
Journal:  J Med Virol       Date:  2007-10       Impact factor: 2.327

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.